This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thoratec's CEO Discusses Q4 2011 Results - Earnings Call Transcript

We caution you that these statements are only predictions and that actual results may differ materially. We also alert you to the risks contained in the documents we file with the Securities and Exchange Commission, such as our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake any obligation to update or correct any forward-looking statements. Gary?

Gerhard F. Burbach

Thank you, Taylor, and good afternoon. 2011 was another exciting year for Thoratec including solid financial performance, continued development of the market for mechanical circulatory support, the acquisition of the CentriMag and PediMag franchise from Levitronix, and important advances in our broad product pipeline.

Our fourth quarter performance reflects strong momentum for the company as we enter 2012, and strategically, I’m very pleased with the company’s positioning for this year and beyond.

With HeartMate II, CentriMag and PVAD, Thoratec offers proven market leading solutions for the full range of mechanical circulatory support needs. In the coming years, we are planning to aggressively grow the market with these flagship products, while at the same time supplementing our core product portfolio with potential breakthrough technological advances, such as our fully magnetically levitated HeartMate III pump platform, our fully implantable LVAD system, and our percutaneous heart pump.

Supporting all of these efforts is the dedicated team at Thoratec in which we’ve been investing heavily, and which we believe provides an unrivaled foundation to serve and support the broader mechanical circulatory support market.

I’m proud of the Thoratec’s success in 2011, but I’m even more enthusiastic about the opportunity ahead as we seek to continue to penetrate the large addressable population of heart failure patients, advance new technologies and extend our market leadership position.

On today’s call, I’ll provide highlights of the fourth quarter and fiscal year 2011. And in the process, provide some additional operating metrics for our business. I’ll then focus on our key initiatives and outlook for 2012.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs